Drugs

, Volume 70, Issue 18, pp 2343–2356

The Potential Role of B Cell-Targeted Therapies in Multiple Sclerosis

  • Aaron Boster
  • Daniel P. Ankeny
  • Michael K. Racke
Leading Article

DOI: 10.2165/11585230-000000000-00000

Cite this article as:
Boster, A., Ankeny, D.P. & Racke, M.K. Drugs (2010) 70: 2343. doi:10.2165/11585230-000000000-00000

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS. Until recently, most therapeutic interventions have targeted T cells in the treatment of MS. Recent data show that B cells also have a role in the pathogenesis of MS. The cerebrospinal fluid and CNS of MS patients contain B cells, plasma cells and immunoglobulins, and recent data indicate that B cells are involved in antigen presentation and T-cell activation, cytokine production, antibody secretion, demyelination and remyelination in MS. These advances in the understanding of B cells and their role in the pathophysiology of MS provide a strong rationale for B cell-targeted therapies. Recent clinical trials with rituximab highlight the possibility that B cells should be an important therapeutic target in patients with MS.

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Aaron Boster
    • 1
    • 2
  • Daniel P. Ankeny
    • 1
    • 2
  • Michael K. Racke
    • 1
    • 2
  1. 1.Department of NeurologyThe Ohio State University Medical CenterColumbusUSA
  2. 2.Department of NeuroscienceOhio State UniversityColumbusUSA

Personalised recommendations